ClinicalTrials.gg
CompletedNCT06425198Updated Jan 22, 2025

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

A Phase 1 interventional study of BMS-986278 in Hepatic Impairment and Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Diseases by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Liver Diseases · Bristol-Myers Squibb.

Started
2024
with 2 others
Phase 1
7 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Liver Diseases by Bristol-Myers Squibb, this one is one of 3 that started in 2024, is one of 7 in phase 1, and was the 10th registered.

Liver Diseases

824 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

None of the 11 studies in Liver Diseases by Bristol-Myers Squibb is open now. The open studies under Liver Diseases, anywhere →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Liver Diseases by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.

03

Conditions studied

  • Hepatic Impairment
  • Healthy Participants

Keywords

  • Healthy Volunteers
  • Pharmacokinetics
  • Liver Diseases
  • Mild, Moderate and Severe Hepatic Impairment
  • BMS-986278
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Must have a (BMI) between 18 and 40 kg/m\^2 (inclusive), and body weight ≥ 50 kg.

Mild, Moderate, or Severe Hepatic Impairment Participants:

  • Mild, moderate, or severe hepatic impairment (HI) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
  • Mild, moderate, and severe HI participants will be enrolled according to the classification score.

Matched Healthy Participants:

  • Free of any disease that would interfere with the study evaluations.
  • Normal hepatic function participants will be enrolled and matched individually with HI participants with respect to age (± 10 years), weight (± 20%), sex, and race/ethnicity (Japanese and Chinese participants vs non-Japanese and non-Chinese participants).

Exclusion criteria

Exclusion Criteria:

All Participants:

  • History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women, or 14 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  • Must not have had any prior exposure to BMS-986278.

Mild, Moderate, or Severe Hepatic Impairment Participants:

  • Acute liver disease (eg, caused by an acute infection or drug toxicity).
  • History of initial stage/planned liver transplantation within 6 months of screening or has received a liver transplant.

Matched Healthy Participants:

  • Any significant medical condition, or psychiatric illness that would prevent participant from participating in the study.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Group A: Mild Hepatic Impairment BMS-986278

    Drug: BMS-986278

  • Experimental
    Group B: Moderate Hepatic Impairment BMS-986278

    Drug: BMS-986278

  • Experimental
    Group C: Severe Hepatic Impairment BMS-986278

    Drug: BMS-986278

  • Experimental
    Group D: Normal Hepatic Function BMS-986278

    Drug: BMS-986278

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to day 9

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to day 9

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to day 9

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 62 days

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to 62 days

  3. Number of participants with physical examination abnormalities

    Time frame: Up to 62 days

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 62 days

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 62 days

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 62 days

  7. Time of maximum observed concentration (Tmax)

    Time frame: Up to day 9

  8. Terminal elimination half-life (T-HALF)

    Time frame: Up to day 9

  9. Apparent body clearance (CLT/F)

    Time frame: Up to day 9

  10. Maximum observed plasma concentration of unbound drug (Cmax_u)

    Time frame: Up to day 9

  11. Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration of unbound drug [AUC(0-T)_u]

    Time frame: Up to day 9

  12. Area under the plasma concentration-time curve from time 0 extrapolated to infinite time of unbound drug [AUC(INF)_u]

    Time frame: Up to day 9

07

Study locations

4 sites
  • Local Institution - 0001
    Miami Lakes, Florida 33027, United States
  • Local Institution - 0003
    Orlando, Florida 32809, United States
  • Local Institution - 0002
    Tampa, Florida 33618, United States
  • Local Institution - 0004
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2024, 6 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2024
First posted
May 22, 2024
StartActual
Jun 10, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06425198
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Jun 10, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Jan 22, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion